Lilly buys the dual-payload ADC specialist before it’s dosed a single patient.
ApexOnco Front Page
Recent articles
After setbacks, cema-cel might have a path to approval in lymphoma.
Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
Arcellx and AstraZeneca take centre stage.
Five years after settling, GSK is again accused of breaching the Jemperli deal.
The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
And AbbVie and Genmab scoop their ASH presentation with new data.
